Compare Nuwellis Inc (NUWE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Nuwellis Inc trades at $2.95 (market cap $1.09M), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | XBI | |
|---|---|---|
Market Cap | $1.09M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $527.46 | $164.28 |
52-Week Low | $2.80 | $85.16 |
Enterprise Value | -$722.58K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
